https://onco-this-week.com/fda-fast-track-designation-for-bgb-b2033-as-treatment-for-hcc/ 2025-12-22T19:29:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-muzastotug-adg126/ 2025-12-22T19:30:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-plt012-in-solid-tumors/ 2025-12-22T19:35:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/tecvayli-plus-darzalex-faspro-combination-selected-for-commissioners-national-priority-voucher-pilot-program/ 2025-12-22T19:36:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/successful-type-c-meeting-with-us-fda-regarding-ph-2b-trial-of-ost-her2-in-the-prevention-or-delay-of-recurrent-fully-resected-pulmonary-metastatic-osteosarcoma-announced/ 2025-12-22T19:42:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-application-to-initiate-a-ph-1-trial-of-abp-102-ct-p72-for-her2-positive-cancers-submitted-to-the-us-fda/ 2025-12-22T19:43:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/roxadustat-granted-orphan-drug-designation-for-the-treatment-of-mds-by-the-us-fda/ 2025-12-22T19:44:05+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/encouraging-clinical-results-with-in-situ-conversion-therapy-nxl-004-for-malignant-glioma-reported/ 2025-12-22T19:45:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/nccn-duvelisib-copiktra-update-to-clinical-practice-guidelines-in-oncology-for-ctcl/ 2025-12-22T19:47:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/padcev-keytruda-combo-significantly-improves-survival-for-mibc-patients-regardless-of-cisplatin-eligibility/ 2025-12-22T19:50:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/clinical-activity-of-mrt-2359-enzalutamide-combo-in-heavily-pretreated-metastatic-crpc-patients-with-androgen-receptor-mutations-announced/ 2025-12-22T19:52:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/preliminary-analysis-shows-80-recurrence-rate-reduction-in-the-open-label-arm-of-flamingo-01/ 2025-12-22T19:57:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/cta-submitted-in-the-uk-for-first-in-human-study-of-zi-ma4-1-zima-101-for-solid-tumors/ 2025-12-22T19:58:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ph-1b-study-of-nxp900-osimertinib-combo-in-nsclc-patients-initiated/ 2025-12-22T20:00:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/athira-pharma-announces-exclusive-license-to-lasofoxifene-ph-3-development-program-for-metastatic-breast-cancer-candidate-and-financing-for-up-to-236m/ 2025-12-22T20:01:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/university-of-chicago-extends-collaboration-with-abbvie-to-advance-clinical-research-and-patient-outcomes-in-oncology/ 2025-12-22T20:03:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/orum-therapeutics-secures-us100m-to-accelerate-development-of-leading-degrader-adc-programs-to-treat-serious-diseases/ 2025-12-22T20:07:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3k%ce%b1-inhibitor-program-2/ 2025-12-22T20:10:59+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/trethera-receives-2-7m-nih-grant-for-tre-515-to-overcome-kras-inhibitor-resistance-in-lung-cancer/ 2025-12-22T20:12:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/harbour-biomed-enters-into-global-strategic-collaboration-and-license-agreement-with-bms-to-discover-and-develop-next-gen-multi-specific-antibodies/ 2025-12-22T20:13:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/promising-efficacy-and-translational-data-supporting-pelareorep-in-kras-mutant-metastatic-crc-announced/ 2025-12-22T20:14:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/anktiva-with-bcg-demonstrates-96-survival-at-three-years-with-median-survival-not-yet-reached-in-bcg-unresponsive-high-grade-papillary-only-nmibc/ 2025-12-22T20:14:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/caris-life-sciences-announces-collaboration-with-genentech-to-discover-novel-therapeutic-targets-in-cancers-with-high-unmet-clinical-need/ 2025-12-22T20:16:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/anixa-biosciences-announces-transfer-of-ind-for-breast-cancer-vaccine-from-cleveland-clinic/ 2025-12-22T20:17:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/first-pancreatic-cancer-patient-in-global-ph-3-registrational-trial-mapkeeper-301-to-be-dosed-in-mid-2026/ 2025-12-30T18:27:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/japans-mhlw-approves-minjuvi-tafasitamab-in-combination-with-rituximab-and-lenalidomide-for-adult-patients-with-2l-fl/ 2025-12-30T22:38:29+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-approves-lunsumio-velo-for-subcutaneous-use-in-r-r-fl/ 2025-12-30T22:39:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/positive-scientific-advice-from-ema-on-the-design-of-a-ph-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma-pdac-announced/ 2025-12-30T22:40:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/enhertu-granted-breakthrough-therapy-designation-in-the-us-as-post-neoadjuvant-therapy-for-patients-with-her2-positive-early-breast-cancer/ 2025-12-30T22:41:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-filed-with-the-us-fda-for-ala-101-ph-1-clinical-trial/ 2025-12-30T22:43:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nda-for-savolitinib-for-locally-advanced-metastatic-gc-gej-adenocarcinoma-patients-with-met-amplification-accepted-and-granted-priority-review-by-the-china-nmpa/ 2025-12-30T22:44:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/12-month-os-data-from-ph-2a-trial-of-atebimetinib-mgnp-in-1l-pancreatic-cancer-patients-to-be-announced-on-jan-7-2026/ 2025-12-30T22:48:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/failed-trial-latify-ph-3-trial-of-ceralasertib-imfinzi-did-not-meet-the-os-primary-endpoint-vs-soc-docetaxel-in-nsclc-patients/ 2025-12-30T22:49:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/update-provided-on-pivotal-ph-3-regal-trial-of-galinpepimut-s-gps-in-aml-no-outcome-analyses-performed/ 2025-12-30T22:53:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/clinical-development-of-acasunlimab-to-be-discontinued-following-portfolio-review/ 2025-12-30T22:55:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-commercial-doses-of-pylclari-for-patients-with-prostate-cancer-in-poland-announced/ 2025-12-30T22:57:33+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/enrollment-progress-update-provided-on-ph-3-terzo-study-of-copiktra-duvelisib-in-adults-with-r-r-nodal-tfhl/ 2025-12-30T22:58:55+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1b-2-tenacity-01-trial-of-ctd402-car-t-cell-therapy/ 2025-12-30T23:00:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-3-alpacca-trial-of-firmonertinib-in-1l-egfr-pacc-mutant-nsclc/ 2025-12-30T23:01:40+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ramp-203-ph-1-2-trial-in-advanced-kras-g12c-mutant-nsclc-discontinued/ 2025-12-30T23:02:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/pidnarulex-cx-5461-enhertu-combo-to-be-evaluated-in-ph-1b-trial-in-her2-positive-and-her2-low-solid-tumors-and-breast-cancer-patients/ 2025-12-30T23:04:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/gmp-manufacturing-of-aktx-101-adc-program-initiated-to-support-ph-1-first-in-human-clinical-trial/ 2025-12-30T23:05:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/lixte-biotechnology-the-university-of-texas-md-anderson-cancer-center-and-gsk-expand-collaboration-on-lb-100-to-treat-ovarian-clear-cell-cancer/ 2025-12-30T23:06:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/athira-pharma-announces-exclusive-license-to-lasofoxifene-ph-3-development-program-for-metastatic-breast-cancer-candidate-and-financing-for-up-to-236m-2/ 2025-12-30T23:07:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/faron-announces-strategic-collaboration-with-the-institute-for-cancer-research-to-launch-blaze-trial-of-bexmarilimab-zimberelimab/ 2025-12-30T23:09:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/jacobio-pharma-enters-global-exclusive-license-agreement-with-astrazeneca-for-pan-kras-inhibitor-jab-23e73/ 2025-12-30T23:11:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/oncodesign-precision-medicine-and-navigo-proteins-announce-the-end-of-their-collaboration-in-the-development-of-radiotheranostics/ 2025-12-30T23:13:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/abl-bio-receives-upfront-payment-for-license-research-and-collaboration-agreement-for-grabody-platform-and-equity-investment-from-lilly/ 2025-12-30T23:13:59+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/harbour-biomed-enters-into-long-term-strategic-collaboration-with-lannacheng-to-advance-next-gen-radionuclide-drug-conjugates/ 2025-12-30T23:15:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/nmpa-approves-tabosun-tyvyt-combo-for-the-neoadjuvant-treatment-of-patients-with-stage-iib-iii-resectable-msi-h-dmmr-colon-cancer/ 2026-01-13T14:20:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/breakthrough-therapy-designation-granted-in-china-for-sacituzumab-tirumotecan-sac-tmt-pembrolizumab-for-1l-pd-l1-positive-nsclc/ 2026-01-13T14:22:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-approval-for-itgb6-targeted-adc-skb105-received-from-the-nmpa/ 2026-01-13T14:25:01+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-application-submitted-to-fda-for-ala-101-allogeneic-car-inkt-cell-therapy-targeting-cd19-positive-nhl-and-leukemias/ 2026-01-13T14:28:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/data-reported-from-ongoing-ph-2a-study-for-bi-1808-with-keytruda-in-recurrent-ovarian-cancer/ 2026-01-13T14:30:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ramp-203-ph-1-2-trial-for-advanced-kras-g12c-mutant-nsclc-halted/ 2026-01-13T14:31:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/phase-iii-stage-of-the-ongoing-ph-2-3-trial-of-surufatinib-camrelizumab-combo-for-1l-pancreatic-ductal-adenocarcinoma-initiated/ 2026-01-13T14:32:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/abbvie-secured-global-rights-outside-china-to-zg006-alveltamig-developed-by-suzhou-zelgen-biopharmaceuticals/ 2026-01-13T14:37:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/bioatla-and-gatc-health-announce-a-40m-spv-transaction-to-advance-ozuriftamab-vedotin-oz-v-into-a-registrational-trial-for-2l-opscc/ 2026-01-13T14:38:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/abl-bio-receives-upfront-payment-for-license-research-and-collaboration-agreement-for-grabody-platform-and-equity-investment-from-lilly-2/ 2026-01-13T14:41:03+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/harbour-biomed-enters-into-long-term-strategic-collaboration-with-lannacheng-to-advance-next-gen-radionuclide-drug-conjugates-2/ 2026-01-13T14:42:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/insilico-medicine-announces-us888m-multi-year-collaboration-with-servier-for-drug-discovery-and-development-in-oncology/ 2026-01-13T14:43:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-orphan-drug-designation-for-arb1002-for-the-treatment-of-pancreatic-cancer/ 2026-01-21T22:55:29+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/breakthrough-therapy-designation-granted-to-zoldonrasib-for-previously-treated-kras-g12d-mutated-locally-advanced-or-metastatic-nsclc/ 2026-01-21T22:55:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-kln-1010-for-r-r-multiple-myeloma/ 2026-01-21T22:57:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/breakthrough-therapy-designation-in-the-us-and-china-for-sevabertinib-in-1l-her2-mutant-nsclc/ 2026-01-21T22:59:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nmpa-approves-ind-for-itgb6-targeted-adc-skb105/ 2026-01-21T23:00:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-alignment-on-use-of-pfs-as-primary-endpoint-in-ph-3-versatile-003-trial-announced/ 2026-01-21T23:01:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-enolen-for-localized-prostate-cancer/ 2026-01-21T23:02:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-for-a2b543-for-mesothelin-expressing-solid-tumors-lacking-hla-a02-expression/ 2026-01-21T23:03:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-clearance-for-hwk-007-and-ind-submission-for-hwk-016-announced/ 2026-01-21T23:05:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-otp-01-in-solid-tumors/ 2026-01-21T23:07:51+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/successful-pre-ind-fda-meeting-and-continued-progress-toward-first-in-human-trial-of-erna-101-in-ovarian-cancer-announced/ 2026-01-21T23:08:49+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-study-may-proceed-letter-for-z-endoxifen-ind-application-for-metastatic-breast-cancer-received/ 2026-01-21T23:09:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-grants-orphan-drug-designation-to-ck0804-treg-therapy-for-treatment-of-myelofibrosis/ 2026-01-21T23:10:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-ind-clearance-for-abp-102-ct-p72-in-solid-tumors-announced/ 2026-01-21T23:11:55+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/regulatory-clearances-of-ind-applications-for-cr-001-cr-003-for-the-treatment-of-solid-tumors-announced/ 2026-01-21T23:13:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/64-os-at-12-months-announced-in-1l-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp/ 2026-01-21T23:14:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ziihera-zanidatamab-hrii-results-in-1l-her2-locally-advanced-or-metastatic-gea-announced-including-2-years-median-os-benefit/ 2026-01-21T23:16:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/fda-fast-track-designation-for-etx-19477-for-brca-mutated-platinum-resistant-ovarian-cancer-patients-announced/ 2026-01-21T23:17:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/positive-topline-results-from-pivotal-study-of-tafasitamab-monjuvi-minjuvi-in-1l-dlbcl-announced/ 2026-01-21T23:18:29+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/strong-topline-ph-2-results-for-dsp107-in-combination-with-anti-pd-l1-therapy-in-crc-announced/ 2026-01-21T23:19:33+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/vyloy-zolbetuximab-chemo-associated-with-enhanced-survival-outcomes-when-common-adverse-events-are-effectively-managed-according-to-new-ad-hoc-analyses/ 2026-01-21T23:20:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-acr-368-ph-2b-endometrial-cancer-clinical-data-with-eu-expansion-to-accelerate-enrollment-initial-acr-2316-clinical-data-and-acr-6840-data-announces/ 2026-01-21T23:22:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/braftovi-regimen-with-additional-chemo-backbone-increased-response-rates-for-certain-patients-with-metastatic-crc/ 2026-01-21T23:23:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/data-from-ph-1-2-trial-of-multi-antigen-targeted-t-cells-in-patients-with-pancreatic-cancer-announced/ 2026-01-21T23:24:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/encouraging-interim-data-of-systemic-administration-of-olvi-vec-in-ongoing-lung-cancer-trials-reported/ 2026-01-21T23:26:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/promising-data-from-ongoing-ph-2a-study-for-bi-1808-with-keytruda-in-recurrent-ovarian-cancer-reported/ 2026-01-21T23:28:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-1-trial-of-st-01156/ 2026-01-21T23:29:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/clinical-update-provided-on-ph-1-trial-of-cer-1236-in-aml-certaint-1-highlighting-key-safety-and-efficacy-data-observed-in-a-patient-with-mds-aml/ 2026-01-21T23:30:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ph-3-kandlelit-007-trial-of-calderasib-mk-1084-keytruda-qlex-initiated-in-certain-patients-with-advanced-nsclc/ 2026-01-21T23:32:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/pierre-fabre-laboratories-and-iktos-announce-integrated-drug-discovery-collaboration/ 2026-01-21T23:33:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/iktos-announces-strategic-collaboration-with-servier/ 2026-01-21T23:34:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/parabilis-medicines-announces-oversubscribed-305-million-financing-to-support-ongoing-fog-001-zolucatetide-clinical-development/ 2026-01-21T23:36:48+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/disco-pharmaceuticals-enters-license-agreement-to-advance-novel-cancer-surfaceome-targeted-therapies/ 2026-01-21T23:37:42+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/storm-therapeutics-and-alidabio-announce-strategic-collaboration-to-accelerate-development-of-cancer-therapies-targeting-rna-modifications/ 2026-01-21T23:38:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/synaffix-and-sidewinder-therapeutics-announce-multi-target-license-agreement-to-advance-development-of-next-gen-bispecific-adcs/ 2026-01-21T23:46:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/anaptys-files-motion-to-dismiss-tesaros-claim-of-anticipatory-breach-of-contract-in-ongoing-litigation-against-tesaro/ 2026-01-21T23:47:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/medilink-signs-an-additional-exclusive-licensing-agreement-with-roche/ 2026-01-21T23:48:48+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/amgen-acquires-dark-blue-therapeutics/ 2026-01-21T23:49:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/renovaro-provides-update-to-definitive-agreement-with-predictive-oncology/ 2026-01-21T23:50:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ind-application-submitted-for-gtb-5550-trike-for-b7-h3-expressing-solid-tumor-cancers/ 2026-01-25T01:35:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-grants-ipn60340-ict01-breakthrough-therapy-designation-in-1l-unfit-aml/ 2026-01-25T01:36:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-orphan-drug-designation-for-gotistobart-in-squamous-nsclc/ 2026-01-25T01:37:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-alignment-received-on-registrational-studies-design-for-ndv-01-for-2l-refractory-high-grade-nmibc-and-in-intermediate-risk-nmibc-in-the-adjuvant-setting/ 2026-01-25T01:39:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/bla-submitted-to-us-fda-seeking-approval-for-ivonescimab-chemo-combo-in-2l-egfrm-nsclc/ 2026-01-25T01:40:55+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-grants-orphan-drug-designation-granted-to-np-g2-044-for-the-treatment-of-pancreatic-cancer/ 2026-01-25T01:42:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-disp-10-in-solid-tumors/ 2026-01-25T01:43:33+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-grants-rmat-designation-to-ect204-for-advanced-hcc/ 2026-01-25T01:45:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/durable-complete-response-of-15-months-with-a-chemo-free-cd19-car-nk-cell-therapy-in-waldenstrom-lymphoma-announced/ 2026-01-25T01:47:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-biomarker-data-from-ph-2b-trial-of-ost-her2-in-the-prevention-or-delay-of-recurrent-fully-resected-pulmonary-metastatic-osteosarcoma-announced/ 2026-01-25T01:48:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/vigil-demonstrates-significant-survival-benefit-in-ctmb-h-hrp-ovarian-cancer-patients-ph-2b-vital-trial-analysis-published-in-jco-precision-oncology/ 2026-01-25T01:49:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/tecvayli-monotherapy-demonstrates-superior-pfs-and-os-vs-soc-in-patients-with-r-r-multiple-myeloma/ 2026-01-25T01:51:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/results-from-sachi-ph-3-trial-of-savolitinib-and-osimertinib-combination-in-egfr-mutationve-nsclc-patients-with-met-amplification-published-in-the-lancet/ 2026-01-25T01:53:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-1-2a-data-of-imc002-highlighted-a-durable-complete-response-beyond-1-year-and-a-66-7-orr-in-advanced-gc-gej/ 2026-01-25T01:54:48+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-results-demonstrating-anktiva-as-a-lymphocyte-stimulating-agent-in-combination-with-checkpoint-inhibitors-in-nsclc-announced/ 2026-01-25T01:56:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-3-kandlelit-007-trial-of-calderasib-keytruda-qlex-merck-initiated-in-certain-patients-with-advanced-nsclc/ 2026-01-25T02:04:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/tropion-lung17-trop2-biomarker-directed-ph-3-trial-of-datroway-initiated-in-patients-with-previously-treated-advanced-nonsquamous-nsclc/ 2026-01-25T02:05:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/tahoe-therapeutics-and-alloy-therapeutics-to-form-joint-venture-and-develop-first-in-class-adcs-for-hard-to-treat-cancers/ 2026-01-25T02:07:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ferring-pharmaceuticals-and-theralase-technologies-to-investigate-adstiladrin-ruvidar-tld-1433-combo-in-bladder-cancer/ 2026-01-25T02:08:28+00:00 https://onco-this-week.com/abbvie-and-remegen-announce-exclusive-licensing-agreement-to-develop-rc148-for-advanced-solid-tumors/ 2026-01-25T02:09:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/boehringer-ingelheim-announces-clinical-collaboration-with-jazz-pharmaceuticals-to-advance-her2-targeted-therapy-in-breast-cancer/ 2026-01-25T02:11:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/bio-sourcing-zerion-pharma-to-collaborate-on-first-her2-oral-monoclonal-antibody-for-breast-cancer/ 2026-01-25T02:13:49+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/medilink-therapeutics-and-roche-to-develop-and-commercialize-yl201-across-numerous-solid-tumor-types/ 2026-01-25T02:15:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/nuvation-bio-and-eisai-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-us-china-and-japan/ 2026-01-25T02:16:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/oricell-therapeutics-announces-70m-initial-closing-of-series-c-financing-to-accelerate-global-development-of-solid-tumor-car-t-therapies/ 2026-01-25T02:17:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/summit-therapeutics-and-gsk-to-evaluate-ivonescimab-in-combination-with-gsks-b7-h3-adc/ 2026-01-25T02:18:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/topline-results-for-epcoritamab-duobody-cd3xcd20-from-ph-3-epcore-dlbcl-1-trial-in-patients-with-r-r-dlbcl-announced/ 2026-01-25T02:19:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/continued-zenocutuzumab-treatment-beyond-progression-shows-benefit-in-patients-with-nrg1-pancreatic-cancer-and-cholangiocarcinoma-from-the-enrgy-trial/ 2026-01-25T02:19:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/rybrevant-amivantamab-vmjw-longer-term-results-show-promising-and-durable-responses-in-difficult-to-treat-crc/ 2026-01-25T02:19:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-follow-up-data-from-ph-2-trial-shows-extended-long-term-os-benefit-with-elraglusib-chemo-for-metastatic-pancreatic-cancer/ 2026-01-25T02:19:40+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/enrollment-of-20th-patient-for-formal-interim-analysis-in-phase-2-ngc-cap-breast-cancer-study-completed/ 2026-01-25T22:38:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ind-application-to-the-us-fda-for-fg001-in-patients-with-high-grade-glioma-hgg/ 2026-01-25T23:15:42+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nda-submission-initiated-for-bezuclastinib-under-real-time-oncology-review-rtor/ 2026-01-25T23:17:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/orphan-drug-designation-granted-to-opn-2853-zavabresib-for-the-treatment-of-myelofibrosis/ 2026-01-25T23:24:33+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-grants-breakthrough-therapy-designation-to-wu-cart-007-for-treatment-of-r-r-t-all-lbl/ 2026-01-25T23:25:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-bnt113-in-hpv16-head-and-neck-cancer/ 2026-01-25T23:28:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-fap-exatecan-ava6103/ 2026-01-25T23:32:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/bbi-940-ind-in-metastatic-breast-cancer-accepted-potentiate-trial-discontinued/ 2026-01-25T23:34:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/sofetabart-mipitecan-receives-us-fda-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer/ 2026-01-25T23:35:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-ind-for-ph-1-trial-of-abl206-neok001/ 2026-01-25T23:37:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/lp-284-receives-fda-orphan-drug-designation-for-soft-tissue-sarcomas/ 2026-01-25T23:38:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-a-unite-based-self-amplifying-rna-vaccine-for-tnbc/ 2026-01-25T23:39:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/regulatory-discussions-with-fda-on-potential-resubmission-path-for-anktiva-in-bcg-unresponsive-papillary-bladder-cancer-advanced/ 2026-01-25T23:40:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-accepts-nda-for-gedatolisib-in-hr-her2-pik3ca-wt-advanced-breast-cancer/ 2026-01-25T23:41:40+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-clears-two-ind-applications-enabling-ph-1-trial-of-d3s-003-and-ph-2-combo-study-of-elisrasib-d3s-001-with-d3s-002/ 2026-01-25T23:42:51+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-use-of-commercially-manufactured-gp2-in-flamingo-01/ 2026-01-25T23:44:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-sets-draft-rules-for-using-mrd-for-supporting-accelerated-approvals-in-multiple-myeloma/ 2026-01-25T23:45:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/enhertu-pertuzumab-type-ii-variation-application-validated-in-the-eu-in-1l-her2ve-metastatic-breast-cancer/ 2026-01-25T23:46:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/median-os-not-yet-reached-and-lymphopenia-reversed-in-recurrent-gbm-patients-receiving-anktiva-plus-car-nk-chemo-free-therapy/ 2026-01-25T23:47:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-interim-results-announced-from-pk-cohort-of-cleer-001-trial-of-ht-001-in-cancer-patients-receiving-egfr-inhibitor-therapy/ 2026-01-25T23:48:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/os-primary-endpoint-met-in-pivotal-ph-3-rosella-trial-of-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer/ 2026-01-25T23:49:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/nejm-publishes-ph-3-ascent-04-keynote-d19-results-of-trodelvy-keytruda-in-1l-pd-l1-metastatic-tnbc/ 2026-01-25T23:50:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-results-from-ph-1b-2-pesco-trial-of-mvp-s-with-keytruda-and-low-dose-cyclophosphamide-for-patients-with-recurrent-epithelial-ovarian-cancer-eoc-announced/ 2026-01-25T23:52:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/5-year-data-for-intismeran-autogene-keytruda-combo-demonstrated-sustained-rfs-improvement-in-high-risk-stage-iii-iv-melanoma-following-complete-resection/ 2026-01-25T23:53:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/updated-interim-data-from-ph-2-advanced-2-trial-of-tara-002-in-bcg-unresponsive-nmibc-patients-to-be-presented/ 2026-01-25T23:54:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-1-2-program-initiated-for-elraglusib-in-refractory-melanoma-and-additional-target-solid-tumor-and-heme-cancers/ 2026-01-25T23:56:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-irb-approval-for-aptn-101s-ph-1-trial-in-gbm-granted-enabling-patient-recruitment-to-begin/ 2026-01-25T23:58:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/janux-therapeutics-and-bristol-myers-squibb-to-develop-a-novel-tumor-activated-therapeutic-for-solid-tumors/ 2026-01-25T23:59:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/infinitopes-expands-seed-financing-to-35m-to-accelerate-clinical-development-of-precision-cancer-vaccine/ 2026-01-26T00:00:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/alteogen-announces-exclusive-license-agreement-with-tesaro-for-the-development-of-a-sq-formulation-of-dostarlimab-enabled-by-hybrozyme-technology/ 2026-01-26T00:01:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-ind-approval-for-neok001-for-treatment-of-solid-tumor-cancers/ 2026-01-26T00:40:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fourth-consecutive-case-of-response-from-ph-1-data-for-the-combination-of-ab8939-with-venetoclax-in-r-r-aml-reported/ 2026-02-01T15:08:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/darzalex-faspro-based-quadruplet-regimen-approved-in-the-us-for-1l-transplant-ineligible-multiple-myeloma-patients/ 2026-02-01T19:49:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-approves-larger-vial-size-for-nelarabine-iv-administration-for-the-treatment-of-t-all-and-t-lbl/ 2026-02-01T19:50:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/chmp-positive-opinion-for-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-metastatic-hspc-with-brca1-2-mutations/ 2026-02-01T19:51:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nda-submitted-to-fda-for-lirafugratinib-in-2l-cholangiocarcinoma/ 2026-02-01T19:53:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-accepts-bla-for-ivonescimab-chemo-in-egfrm-nsclc-post-tki-therapy-pdufa-nov-2026/ 2026-02-01T19:54:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nda-resubmitted-for-rivoceranib-camrelizumab-combo-in-1l-hcc/ 2026-02-01T19:56:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-orphan-drug-designation-for-ctd402-for-the-treatment-of-t-cell-leukemia-and-lymphoma/ 2026-02-01T19:58:03+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/breakthrough-therapy-designation-for-bezuclastinib-in-combination-with-sunitinib-for-gist-patients/ 2026-02-01T19:59:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-ph-3-trial-of-iscib1-in-advanced-melanoma/ 2026-02-01T20:01:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-for-ala-101-accepted-by-us-fda/ 2026-02-01T20:02:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/qtx-2101-awarded-fda-fast-track-designation-for-the-treatment-of-acute-promyelocytic-leukemia/ 2026-02-01T20:03:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-application-cleared-for-an-aav-based-therapy-for-high-grade-glioma-treatment/ 2026-02-01T20:04:55+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/trodelvy-added-as-preferred-regimen-within-1l-metastatic-tnbc-in-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines/ 2026-02-01T20:06:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/lbl-034-granted-fda-fast-track-designation-for-relapsed-refractory-multiple-myeloma/ 2026-02-01T20:07:51+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ibi3003-receives-fda-fast-track-designation-for-relapsed-or-refractory-multiple-myeloma/ 2026-02-01T20:09:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/new-data-demonstrate-cd47-expression-level-helps-predict-response-to-evorpacept-in-combination-with-ziihera-in-her2ve-breast-cancer/ 2026-02-01T20:11:01+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/preliminary-results-from-ph-2-study-of-pds01adc-in-3l-metastatic-crpc-by-the-nci-to-be-presented/ 2026-02-01T20:12:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-update-from-ph-2-trial-of-onvansertib-in-1l-ras-mutated-mcrc-announced/ 2026-02-01T20:13:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-results-from-ph-1b-2-pesco-trial-of-mvp-s-keytruda-and-cyclophosphamide-in-recurrent-epithelial-ovarian-cancer-eoc-reported/ 2026-02-01T20:14:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-ph-2-data-for-maveropepimut-mvp-s-pembrolizumab-and-low-dose-cyclophosphamide-in-metastatic-bladder-cancer-reported/ 2026-02-01T20:15:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/results-announced-from-ph-3-study-of-anbenitamab-kn026-in-her2ve-gastric-or-gastroesophageal-junction-cancer-gc-gej/ 2026-02-01T20:16:44+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/enrollment-completed-for-ph-2b-study-of-bo-112-in-basal-cell-carcinoma-population/ 2026-02-01T20:18:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/key-patent-filed-and-second-adc-program-aktx-102-targeting-ceacam5-expressing-solid-tumors-unveiled/ 2026-02-01T20:19:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ph-3-trial-of-oral-qtx-2101-for-acute-promyelocytic-leukemia-apl-initiated/ 2026-02-01T20:21:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ab-science-receives-notice-of-allowance-for-us-patent-covering-masitinib-in-the-treatment-of-metastatic-crpc/ 2026-02-01T20:22:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/astrazeneca-announced-15b-investment-in-china-through-2030-to-expand-medicines-manufacturing-and-rd/ 2026-02-01T20:25:33+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/wuxi-biologics-and-sinorda-biomedicine-enter-strategic-collaboration-to-accelerate-development-and-manufacturing-of-innovative-bispecific-antibody/ 2026-02-01T20:27:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/hanchorbio-and-wuxi-biologics-enter-strategic-partnership-to-advance-next-gen-bi-and-multi-functional-fusion-protein-pipeline/ 2026-02-01T20:28:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/eikon-therapeutics-secures-350-7m-series-d-to-advance-clinical-stage-programs-and-future-pipeline/ 2026-02-02T15:50:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/first-patient-dosed-in-ph-1-trial-of-rmc-5127-in-patients-with-ras-g12v-mutated-solid-tumors/ 2026-02-02T15:51:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/imfinzi-perioperative-regimen-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-early-gastric-and-gastroesophageal-cancers/ 2026-02-02T15:51:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/positive-initial-ph-1b-data-for-elvn-001-in-cml-reported/ 2026-02-09T16:25:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-3-development-of-bemarituzumab-in-fgfr2b-expressing-gastric-cancer-stopped/ 2026-02-09T16:33:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/fda-approves-label-update-for-yescarta-for-r-r-primary-central-nervous-system-lymphoma/ 2026-02-09T16:33:49+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/ab-science-receives-notice-of-allowance-for-us-patent-covering-masitinib-in-the-treatment-of-metastatic-crpc-2/ 2026-02-09T16:34:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/hookipa-pharma-announces-sale-of-oncology-assets-to-neotrail-therapeutics/ 2026-02-09T16:34:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/first-patient-dosed-in-china-in-etx-636-global-ph-1-2-study/ 2026-02-09T16:35:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/us-investigator-meeting-held-for-ph-3-hlx22-gc-301-in-her2-gastric-cancer/ 2026-02-09T16:35:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1a-2a-trial-of-dptx3186-in-advanced-solid-tumors-focused-on-gastric-cancer/ 2026-02-09T16:35:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ph-2-trial-of-stenoparib-with-temozolomide-in-relapsed-sclc-open-for-enrollment/ 2026-02-09T16:35:38+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/multiple-sites-activated-for-ph-1b-2-trial-of-amxt-1501-and-dfmo-in-patients-with-solid-tumors-including-breast-cancer-and-melanoma/ 2026-02-09T16:35:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/dosing-of-first-cohort-in-ph-1-trial-of-ktx-2001-in-prostate-cancer-completed/ 2026-02-09T16:35:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/patient-recruitment-opened-for-ph-1-trial-of-innocell-in-patients-with-recurrent-epithelial-ovarian-cancer/ 2026-02-09T16:36:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/50-enrolment-in-global-tacti-004-keynote-f91-ph-3-trial-in-1l-nsclc-achieved/ 2026-02-09T16:36:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1-2-trial-of-ds3790-in-patients-with-r-r-b-cell-nhl/ 2026-02-09T16:36:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/positive-year-end-interim-clinical-progress-from-ph-2-study-of-ampligen-imfinzi-combo-in-pancreatic-cancer-reported/ 2026-02-09T16:36:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/datroway-granted-priority-review-in-the-us-in-1l-metastatic-tnbc-patients-who-are-not-candidates-for-immunotherapy/ 2026-02-09T16:36:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/52-amtagvi-response-rate-with-two-or-fewer-prior-lines-of-therapy-73-overall-dcr-in-melanoma-announced/ 2026-02-09T16:36:38+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ind-amendment-for-ph-2a-trial-with-ttx-mc138-in-crc-submitted/ 2026-02-09T16:36:45+00:00 https://onco-this-week.com/fda-grants-orphan-drug-designation-to-cutaneous-melanoma-treatment/ 2026-02-09T16:37:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-accepted-nda-for-zanzalintinib-tecentriq-combo-in-patients-with-metastatic-crc/ 2026-02-09T16:37:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-ph-1-study-of-n17350-in-patients-with-advanced-solid-tumors/ 2026-02-09T16:38:38+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/zovegalisib-granted-breakthrough-therapy-designation-by-fda-for-pik3ca-mutant-hr-her2-advanced-breast-cancer/ 2026-02-09T16:39:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-ph-1-study-of-gtb-5550-trike-for-solid-tumors-expressing-b7-h3/ 2026-02-09T16:39:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-ph-1-study-for-prt12396-for-the-treatment-of-patients-with-myeloproliferative-neoplasms/ 2026-02-09T16:39:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-pelareorep-in-2l-kras-mutant-mss-metastatic-crc/ 2026-02-09T16:39:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/zenocutuzumab-zbco-receives-fda-orphan-drug-designation-for-treatment-of-cholangiocarcinoma/ 2026-02-09T16:39:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/dual-ind-applications-for-allogeneic-bcma-car-t-product-ct05-submitted/ 2026-02-13T21:49:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-approves-novocures-optune-pax-for-the-treatment-of-locally-advanced-pancreatic-cancer/ 2026-02-17T19:03:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-orphan-drug-designation-for-hcb101-in-gastric-cancer/ 2026-02-17T19:04:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-cleared-ind-application-for-npx372-in-b7-h7-expressing-solid-tumors-including-lung-adenocarcinoma-rcc-and-pancreatic-adenocarcinoma/ 2026-02-17T19:05:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ph-3-libretto-432-trial-of-retevmo-selpercatinib-met-primary-endpoint-of-efs-in-patients-with-early-stage-ii-iiia-ret-fusion-positive-nsclc/ 2026-02-17T19:06:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/encouraging-patient-survival-observations-reported-in-ovarian-cancer-lira-cel-car-t-trial-achieves-regulatory-approval-enabling-major-dose-escalation/ 2026-02-17T19:07:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-enrolled-in-ph-1-trial-of-an9025-for-solid-tumors-with-ras-mutations/ 2026-02-17T19:07:59+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/enrollment-completed-in-ph-1-trial-of-senti-202-in-r-r-aml/ 2026-02-17T19:08:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-enrolled-in-global-ph-1-trial-of-an9025-for-solid-tumors-harboring-ras-mutations/ 2026-02-17T19:09:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/carsgen-signs-strategic-cooperation-agreements-to-expand-car-t-commercial-manufacturing-base-in-china/ 2026-02-17T19:11:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/tempest-plans-to-prioritize-development-of-clinical-stage-dual-targeting-cd19-bcma-car-t-program-tpst-2003/ 2026-02-17T19:16:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/keytruda-and-keytruda-qlex-plus-paclitaxel-%c2%b1-bevacizumab-approved-for-2l-3l-pd-l1-cps-%e2%89%a51-platinum-resistant-ovarian-carcinoma/ 2026-02-17T19:19:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/rmat-designation-granted-by-fda-to-kb707-for-the-treatment-of-advanced-or-metastatic-nsclc/ 2026-02-17T19:20:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/50-enrolment-completed-in-tacti-004-keynote-f91-ph-3-trial-in-1l-nsclc/ 2026-02-17T19:21:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/carsgen-and-dispatch-bio-announce-clinical-collaboration-to-evaluate-flare-platform-and-zevor-cel-in-solid-tumors/ 2026-02-17T19:22:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/first-patient-dosed-in-ph-1b-study-of-iadademstat-in-es-sclc/ 2026-02-17T19:23:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-the-pinacle-h2h-ph-3-trial-of-rondecabtagene-autoleucel-ronde-cel-or-lyl314-vs-liso-cel-or-axi-cel-in-2l-r-r-lbcl/ 2026-02-17T19:26:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/calquence-venetoclax-approved-in-the-us-as-oral-fixed-duration-combination-for-1l-cll-patients/ 2026-02-25T15:25:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/european-commission-grants-conditional-marketing-authorization-for-anktiva-bcg-in-bcg-unresponsive-nmibc-cis-with-or-without-papillary-tumors/ 2026-02-25T15:26:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-accepts-nda-for-r-r-pcnsl-pduda-dec-2026/ 2026-02-25T15:27:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-grants-breakthrough-therapy-designation-priority-review-and-accepts-nda-for-iberdomide-in-rrmm-patients-pdufa-aug-2026/ 2026-02-25T15:30:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/adoption-of-amended-protocol-for-ph-3-versatile-003-trial-incorporating-pfs-as-primary-endpoint-for-interim-analysis-and-potential-accelerated-approval-announced/ 2026-02-25T15:32:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/datroway-supplemental-nda-submitted-in-japan-for-patients-with-metastatic-tnbc-who-are-not-candidates-for-immunotherapy/ 2026-02-25T15:33:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/enhertu-type-ii-variation-application-validated-in-the-eu-as-post-neoadjuvant-treatment-for-patients-with-her2ve-early-breast-cancer/ 2026-02-25T15:34:41+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-filed-with-fda-for-ph-2-study-of-tbs-2025-for-the-treatment-of-r-r-mutnpm1-aml-in-combination-with-a-menin-inhibitor/ 2026-02-25T15:36:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-for-fg001-in-high-grade-glioma/ 2026-02-25T15:36:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-fda-breakthrough-therapy-designation-for-patients-with-advanced-head-and-neck-cancer/ 2026-02-25T15:39:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-for-cs2009-pd-1-vegf-ctla-4-to-advance-into-ph-2-clinical-trial/ 2026-02-25T15:40:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/mhra-and-rec-approved-cta-for-ph-1-zima-101-trial-of-zi-ma4-1-in-patients-with-advanced-solid-cancers/ 2026-02-25T15:41:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/first-interim-analysis-in-the-global-phase-3-fierce-hn-study-of-ficlatuzumab-completed/ 2026-02-25T15:42:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/zenocutuzumab-treatment-beyond-progression-demonstrates-continued-benefit-in-patients-with-nrg1-nsclc-in-new-results-from-the-enrgy-trial/ 2026-02-25T15:43:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/planned-milestones-in-ongoing-ph-2-duripanc-trial-of-ampligen-and-durvalumab-in-the-treatment-of-metastatic-pancreatic-cancer-announced/ 2026-02-25T15:44:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-2-study-of-givastomig-nivolumab-combo-in-patients-with-1l-metastatic-her2-neg-gastric-cancer/ 2026-02-25T15:45:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/candel-therapeutics-100m-royalty-funding-agreement-with-rtw-to-support-aglatimagene-besadenovec-can-2409-launch-in-localized-prostate-cancer-announced/ 2026-02-25T15:46:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/sift-biosciences-announces-oversubscribed-3-7m-pre-seed-financing-to-advance-next-gen-t-cell-immunotherapy-platform/ 2026-02-25T15:47:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/surge-therapeutics-raises-32m-series-b-financing-to-advance-intraoperative-immunotherapy-to-improve-cancer-patient-survival-outcomes-post-surgery/ 2026-02-25T15:52:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/sensei-biotherapeutics-announces-acquisition-of-faeth-therapeutics-and-200m-concurrent-private-placement/ 2026-02-25T15:53:05+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/cellares-and-university-of-wisconsin-school-of-medicine-and-public-health-expand-partnership-to-clinical-manufacturing-of-crispr-edited-car-t-for-solid-tumors/ 2026-02-25T15:53:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-approves-monthly-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-in-1l-egfr-nsclc/ 2026-02-25T15:59:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-accepts-nda-for-giredestrant-in-esr1-mutated-er-advanced-breast-cancer-pdufa-dec-2026/ 2026-02-25T16:00:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/braftovi-regimen-improves-pfs-in-metastatic-crc-in-breakwater-trial/ 2026-02-25T16:01:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/bostongene-announces-strategic-collaboration-with-daiichi-sankyo-to-accelerate-drug-development-through-ai-driven-multimodal-analytics/ 2026-02-25T16:08:48+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/mhra-approves-zanidatamab-ziihera-for-the-treatment-of-biliary-tract-cancer/ 2026-02-25T16:10:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel/ 2026-02-25T16:12:01+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-grants-fast-track-designation-to-plt012-in-hcc/ 2026-02-25T16:13:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/biodexa-announces-exclusive-license-of-otsukas-opb-171775-a-ph-1-ready-molecular-glue-for-gist/ 2026-02-25T16:14:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-grants-full-approval-to-braftovi-combination-regimen-in-1l-metastatic-crc/ 2026-03-03T15:24:40+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-tentatively-approves-and-application-for-lutetium-lu-177-dotatate-pnt2003-for-the-treatment-of-somatostatin-receptor-positive-gep-nets/ 2026-03-03T15:26:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-fast-track-designation-for-aky-1189/ 2026-03-03T15:28:59+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-srn-101-for-the-treatment-of-recurrent-high-grade-glioma/ 2026-03-03T15:29:41+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/enhertu-supplemental-nda-submitted-in-japan-as-adjuvant-therapy-for-patients-with-her2-positive-early-breast-cancer/ 2026-03-03T15:30:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/second-positive-idmc-recommendation-for-ph-3-artemia-trial-of-tedopi-in-nsclc/ 2026-03-03T15:31:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/application-for-marketing-authorization-of-zumrad-in-nmibc-withdrawn/ 2026-03-03T15:33:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/adjuvant-keytruda-welireg-reduced-the-risk-of-disease-recurrence-or-death-by-28-vs-keytruda-monotherapy-in-certain-patients-with-earlier-stage-rcc/ 2026-03-03T15:35:03+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/welireg-lenvima-reduced-the-risk-of-disease-progression-or-death-by-30-vs-cabozantinib-in-certain-previously-treated-patients-with-advanced-rcc/ 2026-03-03T15:36:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/keytruda-paclitaxel-bevacizumab-significantly-improved-os-vs-paclitaxel-bevacizumab-in-patients-with-platinum-resistant-recurrent-ovarian-cancer/ 2026-03-03T15:37:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/perioperative-keytruda-padcev-reduced-risk-of-efs-events-by-47-and-risk-of-death-by-35-for-cisplatin-eligible-mibc-patients/ 2026-03-03T15:38:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/zusduri-achieves-durable-complete-responses-across-eortc-risk-groups-in-patients-with-recurrent-lg-ir-nmibc/ 2026-03-03T15:39:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/early-study-results-show-promising-antitumor-activity-with-combination-of-pasritamig-and-docetaxel-in-advanced-prostate-cancer/ 2026-03-03T15:39:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/tara-002-demonstrates-68-complete-response-rate-at-six-months-in-bcg-unresponsive-nmibc/ 2026-03-03T15:43:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/new-real-world-data-reinforce-earlier-use-of-pluvicto-before-chemotherapy-in-metastatic-crpc/ 2026-03-03T15:45:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-results-from-lifileucel-clinical-trial-in-soft-tissue-sarcomas-announced/ 2026-03-03T15:49:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/randomized-ph-2a-study-of-low-dose-alnodesertib-plus-gemcitabine-achieves-primary-endpoint-in-platinum-resistant-ovarian-cancer/ 2026-03-03T15:50:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-1-2-everest-2-study-with-a2b543-in-solid-tumors/ 2026-03-03T15:51:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-2-momentum-trial-of-cemsidomide-in-combination-with-dexamethasone-for-relapsed-refractory-multiple-myeloma/ 2026-03-03T15:52:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/synthekine-and-merck-to-evaluate-stk-012-keytruda-and-chemo-in-ph-2-trial-in-1l-pd-l1-neg-nonsquamous-nsclc/ 2026-03-03T15:53:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/aim-immunotech-signs-agreement-for-planning-of-proposed-ph-3-trial-of-ampligen-in-late-stage-pancreatic-cancer/ 2026-03-03T15:54:29+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/registration-focused-pelareorep-programs-in-anal-and-colorectal-cancer-prioritized/ 2026-03-03T15:55:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-approves-hernexeos-in-1l-her2-mutant-advanced-nsclc/ 2026-03-03T15:56:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-completes-30-day-safety-review-of-two-ind-applications-for-cxcr4-targeted-theranostic-program-in-hemato-oncology-proposed-clinical-study-may-proceed/ 2026-03-03T15:57:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/os-primary-endpoint-met-in-ph-3-rosella-trial-of-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer/ 2026-03-03T15:58:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/fda-places-partial-clinical-hold-on-ph-2-linnet-study-of-lorigerlimab-in-patients-with-gynecologic-cancers/ 2026-03-03T16:00:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/wuxi-xdc-enters-strategic-collaboration-with-earendil-labs-on-wuxitecan-2-payload-linker-technology-platform/ 2026-03-03T16:03:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/sc-rybrevant-approved-by-european-commission-for-q3w-and-q4w-dosing-for-patients-with-advanced-egfr-mutated-nsclc/ 2026-03-03T16:04:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-fast-track-designation-for-art6043-for-treatment-of-gbrca-mutated-her2-negative-breast-cancer/ 2026-03-03T16:05:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/positive-ph-3-interim-topline-results-for-izalontamab-brengitecan-iza-bren-in-unresectable-locally-advanced-or-metastatic-1l-tnbc-highlighted/ 2026-03-03T16:06:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-1-trial-of-ide034/ 2026-03-03T16:08:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/astellas-and-vir-biotechnology-to-advance-psma-targeting-pro-xten-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer/ 2026-03-03T16:09:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-clears-ind-application-for-neok002-in-solid-tumors/ 2026-03-03T16:10:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/encouraging-results-for-225ac-psma-trillium-in-advanced-metastatic-prostate-cancer-reported/ 2026-03-03T16:11:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/fda-approves-tecvayli-darzalex-faspro-for-r-r-2l-multiple-myeloma/ 2026-03-10T13:27:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/european-commission-approves-akeega-niraparib-abiraterone-dual-action-tablet-for-the-treatment-of-patients-with-brca1-2-mutated-metastatic-hspc-patients/ 2026-03-10T13:28:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/ind-application-filed-for-ml-016-for-advanced-solid-tumors-with-lung-and-or-liver-mets/ 2026-03-10T13:29:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-ind-application-for-gntbm-38-for-ph-1-trial-in-advanced-solid-tumors-and-r-r-ptcl/ 2026-03-10T13:30:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-ind-application-for-kst-0651-for-ph-1-trial-in-advanced-solid-tumors-including-pancreatic-cancer-crc-nsclc-and-others/ 2026-03-10T13:32:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-ind-application-for-ph-1-trial-of-kgx105-monotherapy-in-locally-advanced-or-metastatic-solid-tumors/ 2026-03-10T13:32:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nmpa-approves-ind-application-for-hlx97-for-the-treatment-of-advanced-or-metastatic-solid-tumors/ 2026-03-10T13:33:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nmpa-accepts-new-drug-applications-for-toripalimab-subcutaneous-injection-across-12-indications/ 2026-03-10T13:36:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/request-submitted-to-the-fda-for-type-a-meeting-for-tabelecleucel-tab-cel-bla/ 2026-03-10T13:39:40+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/positive-chmp-opinion-for-ojemda-monotherapy-for-pediatric-r-r-braf-altered-pediatric-low-grade-glioma/ 2026-03-10T13:40:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-ost-her2-type-d-meeting-elevated-to-type-b-pre-bla-meeting/ 2026-03-10T13:43:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ph-2-sknjct-003-trial-reported-73-clinical-clearance-and-40-histological-clearance-cr-with-d-mna-in-bcc/ 2026-03-10T19:07:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/namodenoson-meets-safety-primary-endpoint-in-ph-2a-pancreatic-cancer-study/ 2026-03-10T19:09:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/full-results-from-ph-2-chopin-trial-of-percutaneous-hepatic-perfusion-ipilimumab-and-nivolumab-combo-in-metastatic-uveal-melanoma-published-in-the-lancet-oncology/ 2026-03-10T19:11:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/failed-trial-ph-3-study-of-xospata-gilteritinib-did-not-meet-primary-endpoint-of-os-in-patients-with-newly-diagnosed-flt3m-aml/ 2026-03-10T19:12:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-ph-3-results-from-successor-2-study-of-oral-mezigdomide-in-relapsed-or-refractory-multiple-myeloma-announced/ 2026-03-10T19:13:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/agreement-signed-for-planning-of-proposed-ph-3-trial-of-ampligen-for-late-stage-pancreatic-cancer/ 2026-03-10T19:14:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/global-ph-1-2-trial-of-hmpl-a580-initiated-in-patients-with-solid-tumors/ 2026-03-10T19:15:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/akeso-and-inovio-to-advance-cadonilimab-in-combination-with-ino-5412-for-gbm/ 2026-03-10T19:16:42+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-serviers-rare-oncology-portfolio/ 2026-03-10T19:18:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/allarity-therapeutics-announces-final-settlement-with-the-u-s-securities-and-exchange-commission/ 2026-03-10T19:20:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/hopewell-therapeutics-announces-sublicense-of-proprietary-lipid-nanoparticles-for-novel-cancer-vaccine-to-foxcroft-therapeutics/ 2026-03-10T19:22:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/cytodyn-closes-17-5m-financing-to-fund-continued-development-of-leronlimab/ 2026-03-10T19:24:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-1-8m/ 2026-03-10T19:25:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/tempus-announces-strategic-collaboration-agreement-with-merck-to-accelerate-ai-driven-precision-medicine/ 2026-03-10T19:33:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/lisata-therapeutics-enters-into-definitive-agreement-to-be-acquired-by-kuva-labs-inc/ 2026-03-10T19:34:05+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/enhertu-granted-priority-review-in-the-us-as-post-neoadjuvant-treatment-for-patients-with-her2ve-early-breast-cancer/ 2026-03-10T19:47:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/cadonilimab-achieves-100-24-month-os-in-complete-responders-in-r-m-cervical-cancer-based-on-long-term-ph-2-results/ 2026-03-10T19:48:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/hoth-therapeutics-deploys-openai-api-to-advance-development-of-orphan-ht-kit-oncology-program/ 2026-03-10T19:50:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/supplemental-bla-for-anktiva-bcg-in-bcg-unresponsive-nmibc-with-papillary-disease-resubmitted-to-the-fda/ 2026-03-10T19:51:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/failed-trial-persevera-breast-cancer-study-of-giredestrant-palbociclib-combo-did-not-meet-the-primary-objective-of-statistically-significant-pfs-improvement-in-erve-her2-neg-locally-advanced-or-met/ 2026-03-10T19:53:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/persevere-therapeutics-launches-as-a-clinical-stage-oncology-company-with-a-novel-ph-1b-2a-agent-and-announces-first-close-of-seed-financing/ 2026-03-10T19:54:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/12-month-ph-2-interim-data-for-ndv-01-in-nmibc-reported/ 2026-03-10T19:55:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/erasca-and-tango-therapeutics-to-evaluate-combination-of-eras-0015-and-vopimetostat-in-mtapdel-pancreatic-or-mtapdel-rasm-nsclc/ 2026-03-10T19:56:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/imfinzi-approved-in-the-eu-in-patients-with-early-gastric-and-gastroesophageal-cancers/ 2026-03-17T20:41:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-granted-orphan-drug-designation-to-amxt-1501-in-combination-with-difluoromethylornithine-dfmo-for-the-treatment-of-malignant-glioma/ 2026-03-17T20:42:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nda-resubmitted-to-fda-for-tlx101-px-pixclara/ 2026-03-17T20:43:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/combo-regimen-may-improve-pathologic-complete-response-rate-in-tnbc-in-early-ph-2-invincible-4-of-int230-6/ 2026-03-17T20:45:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/mipletamig-delivers-compelling-86-clinical-benefit-rate-and-no-crs-as-evaluable-aml-patient-data-increases-by-nearly-50/ 2026-03-17T20:51:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/zemcelpro-dorocubicel-positive-results-in-high-and-very-high-risk-blood-cancers-to-be-reported/ 2026-03-17T20:52:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/results-from-pik3ca-wt-cohort-of-ph-3-viktoria-1-study-of-gedatolisib-regimens-in-hr-her2-advanced-breast-cancer-published-in-journal-of-clinical-oncology/ 2026-03-17T20:53:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-ph-1-results-for-dt-9081-in-advanced-solid-tumors-announced/ 2026-03-17T20:54:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-2-trial-of-sls009-tambiciclib-in-1l-aml/ 2026-03-17T20:55:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/aditxt-acquires-ignite-proteomics-focused-on-optimizing-therapy-selection/ 2026-03-17T21:03:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/type-a-meeting-with-fda-scheduled-to-discuss-the-crl-to-the-bla-for-tabelecleucel-tab-cel/ 2026-03-17T21:07:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/prostact-ph-3-study-part-1-of-tlx591-tx-achieves-primary-objectives-in-psmave-metastatic-crpc-patients/ 2026-03-17T21:09:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/tazverik-tazemetostat-voluntarily-withdrawn-in-follicular-lymphoma-and-epithelioid-sarcoma/ 2026-03-17T21:18:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ind-application-for-hlx316-approved-in-china/ 2026-03-17T21:19:55+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-nmibc-highlighted/ 2026-03-17T21:21:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/tacti-004-ph-3-study-in-1l-nsclc-to-be-discontinued-following-futility-analysis/ 2026-03-17T21:23:48+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/opdivo-combination-regimens-received-fda-approval-for-previously-untreated-stage-iii-or-iv-chl-and-ec-approval-in-r-r-chl-after-one-prior-line-of-therapy/ 2026-03-24T19:53:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/nccn-guidelines-updated-to-include-anktiva-plus-bcg-for-patients-with-bcg-unresponsive-nmibc-with-papillary-only-disease/ 2026-03-24T19:54:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-granted-orphan-drug-designation-to-irinotecan-chemoseed-for-malignant-glioma/ 2026-03-24T19:55:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/positive-end-of-phase-2-meeting-with-fda-regarding-the-design-of-a-ph-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma-announced/ 2026-03-24T19:56:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-application-of-gt307/ 2026-03-24T19:58:44+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-srn-101-for-the-treatment-of-recurrent-high-grade-glioma-2/ 2026-03-24T20:00:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/talzenna-plus-xtandi-significantly-improves-radiographic-pfs-in-metastatic-prostate-cancer/ 2026-03-24T20:19:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/primary-endpoint-met-in-ph-2-study-fourlight-1-showing-a-40-reduction-in-the-risk-of-disease-progression-or-death-with-manageable-safety-profile/ 2026-03-24T20:20:38+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/hybryte-clinical-summary-published-in-expert-opinion-on-investigational-drugs/ 2026-03-24T20:21:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/extended-long-term-survival-observed-in-ph-2a-trial-in-advanced-nsclc-treated-with-aglatimagene-besadenovec-aglatimagene-or-can-2409/ 2026-03-24T20:22:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/data-from-ph-1-2-rediscover-trial-of-400mg-bid-zovegalisib-rly-2608-fulvestrant-in-patients-with-pi3k%ce%b1-mutated-hr-her2-metastatic-breast-cancer-announced/ 2026-03-24T20:23:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-1a-data-of-tos-358-in-heavily-pretreated-patients-with-pi3k%ce%b1-mutant-metastatic-breast-cancer-and-other-solid-tumors-presented/ 2026-03-24T20:24:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-ph-1-expansion-data-for-epcam-probody-adc-varsetatug-masetecan-varseta-m-in-late-line-metastatic-crc-announced/ 2026-03-24T20:25:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-3-trial-flamingo-01-of-glsi-100-to-prevent-breast-cancer-recurrences-announced-the-initiation-of-new-clinical-sites-in-the-us/ 2026-03-24T20:26:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1-2-trial-of-tri-611-for-the-treatment-of-alk-positive-nsclc/ 2026-03-24T20:27:05+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/45-patient-interim-data-unblinding-in-pivotal-miracle-trial-on-track-for-mid-2026/ 2026-03-24T20:28:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/planned-ph-1-clinical-trial-of-iba101-in-lung-cancer-announced/ 2026-03-24T20:28:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/botbal-program-entered-global-ph-3-evaluation-in-refractory-mss-metastatic-crc/ 2026-03-24T20:29:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/45th-subject-enrolled-in-pivotal-ph-2b-3-miracle-trial-of-annamycin-cytarabine-annarac-for-r-r-aml/ 2026-03-24T20:30:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/excalipoint-therapeutics-launches-with-68-7-million-to-develop-next-gen-t-cell-engager-therapies/ 2026-03-24T20:31:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/glyconex-inc-and-nippon-kayaku-enter-collaboration-to-advance-next-gen-adc-candidate-gnx201-adc/ 2026-03-24T20:33:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/crossbow-therapeutics-raised-77-million-in-series-b-financing-to-support-completion-of-crosscheck-001-ph-1-clinical-trial-of-cbx-250-and-accelerate-development-of-additional-t/ 2026-03-24T20:34:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/trodelvy-added-as-preferred-regimen-within-1l-metastatic-tnbc-in-nccn-guidelines/ 2026-03-24T22:31:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/positive-ph-3-results-from-wu-kong28-study-of-zegfrovy-sunvozertinib-vs-chemo-in-1l-nsclc-with-exon20ins-mutation-announced/ 2026-03-24T22:32:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-3-study-of-jskn016-in-tnbc-patients/ 2026-03-24T22:33:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/novartis-entered-into-an-agreement-with-synnovation-therapeutics-to-acquire-snv4818-for-hr-her2-breast-cancer-and-other-solid-tumor-indications/ 2026-03-24T22:34:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ema-validates-type-ii-variation-application-for-padcev-keytruda-in-cisplatin-eligible-patients-with-muscle-invasive-bladder-cancer/ 2026-03-24T22:35:05+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/mature-median-os-data-from-ongoing-accent-clinical-trial-of-narmafotinib-chemo-in-advanced-pancreatic-cancer-announced/ 2026-03-24T22:36:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-1-2-duravelo-3-trial-for-zelenectide-in-nectin4-amplified-breast-cancer-and-duravelo-4-trial-in-nectin4-amplified-nsclc-to-be-discontinued-trial-design-of-duravelo-2-trial-to-be-changed/ 2026-03-24T22:36:59+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/voro-therapeutics-and-daiichi-sankyo-to-advance-primebody-technology-for-next-gen-tumor-activated-adcs/ 2026-03-24T22:38:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-type-b-meeting-on-potential-accelerated-approval-pathway-for-givastomig-in-gastric-cancer-concluded/ 2026-03-24T22:39:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/enhertu-followed-by-thp-approved-in-china-for-the-neoadjuvant-treatment-of-her2ve-breast-cancer/ 2026-03-31T14:14:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/ema-approves-daratumumab-administration-by-patients-caregivers-for-multiple-myeloma/ 2026-03-31T14:14:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/tri-611-granted-fda-fast-track-designation-for-treatment-of-alkve-nsclc/ 2026-03-31T14:15:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-ind-for-ph-1-pediatric-cns-cancer-trial-of-star-001/ 2026-03-31T14:18:51+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-label-update-to-accelerate-thaw-time-for-adstiladrin-nadofaragene-firadenovec-vncg/ 2026-03-31T14:20:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/rct1213-wins-fda-orphan-drug-designation-for-hcc/ 2026-03-31T14:21:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-accepts-nda-resubmission-for-rivoceranib-in-combination-with-camrelizumab-for-1l-hcc/ 2026-03-31T14:21:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/israeli-ministry-of-health-approves-initiation-of-ph-2-3-trial-of-sil204-for-the-treatment-of-locally-advanced-pancreatic-cancer/ 2026-03-31T14:22:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/japans-pmda-approves-initiation-of-clinical-trial-for-car-t-therapy-equecabtagene-autoleucel-in-2l-3l-multiple-myeloma/ 2026-03-31T14:23:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/zegfrovy-sunvozertinib-shows-antitumor-activity-in-1l-nsclc-patients-with-egfr-pacc-or-other-uncommon-mutations/ 2026-03-31T14:24:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-2-data-announced-for-danburstotug-in-nk-t-cell-lymphoma/ 2026-03-31T14:25:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-topline-results-from-ph-2-panova-4-trial-of-tumor-treating-fields-ttfields-therapy-for-metastatic-pancreatic-cancer-announced/ 2026-03-31T14:26:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/namodenoson-positive-data-in-ph-2a-pancreatic-cancer-and-9-years-cancer-free-survival-in-liver-cancer-patient-announced/ 2026-03-31T14:27:22+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/iph6501-development-in-patients-with-b-nhl-discontinued/ 2026-03-31T14:28:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1b-2-trial-of-hlx701-combination-therapy-in-advanced-crc/ 2026-03-31T14:29:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1b-trial-of-cemsidomide-in-combination-with-elranatamab-elrexfio-for-relapsed-refractory-multiple-myeloma/ 2026-03-31T14:29:39+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-ph-1-trial-of-clio-8221-in-advanced-her2-expressing-solid-tumors/ 2026-03-31T14:30:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/merck-to-acquire-terns-pharmaceuticals-with-tern-701-a-novel-candidate-for-cml/ 2026-03-31T14:34:44+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ubrigene-and-cellinfinity-bio-to-advance-in-vivo-car-t-therapies/ 2026-03-31T14:37:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-approves-lifyorli-relacorilant-plus-nab-paclitaxel-for-treatment-of-patients-with-platinum-resistant-ovarian-cancer/ 2026-03-31T14:39:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-fast-track-designation-granted-to-zw191-for-the-treatment-of-patients-with-advanced-or-metastatic-platinum-resistant-ovarian-cancer-proc/ 2026-03-31T14:41:05+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/updated-ph-2-data-showing-continued-improvement-in-median-os-with-imnn-001-in-women-with-newly-diagnosed-advanced-ovarian-cancer-reported/ 2026-03-31T14:42:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/quilt-2-005-randomized-clinical-trial-on-track-for-final-analysis-and-supplemental-bla-submission-in-2026-for-the-bcg-naive-nmibc-carcinoma-in-situ/ 2026-03-31T14:43:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/japans-mhlw-approves-risovalisib-risovalisib-mesilate-hydrate-or-heitzexin-after-chemo-for-ovarian-clear-cell-carcinoma-with-advanced-pik3ca-gene-mutations/ 2026-03-31T14:44:42+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-provides-ind-clearance-for-neok002-targeting-solid-tumors/ 2026-03-31T14:45:29+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ph-3-sentry-trial-in-myelofibrosis-met-first-co-primary-endpoint-of-spleen-volume-reduction-but-not-abs-tss/ 2026-03-31T14:48:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/second-patient-dosed-in-cohort-2-of-ph-1-cer-1236-trial/ 2026-03-31T14:49:58+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/nmpa-approves-initiation-of-hh101785-clinical-trial-in-solid-tumors/ 2026-03-31T17:36:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ema-validates-maa-for-taletrectinib-for-the-treatment-of-advanced-ros1ve-nsclc/ 2026-04-06T22:57:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-grants-full-approval-of-tecartus-for-adult-patients-with-r-r-mcl/ 2026-04-07T03:55:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/european-commission-approves-keytruda-paclitaxel-%c2%b1-bevacizumab-for-the-treatment-of-adults-with-pd-l1-cps-%e2%89%a51-platinum-resistant-recurrent-ovarian-carcinoma-who-have-received-one-or-tw/ 2026-04-07T03:56:55+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-granted-fast-track-designation-for-a2b543-for-the-treatment-of-germline-heterozygous-hla-a02-adults-with-recurrent-unresectable-locally-advanced-or-metastatic-solid-tumors-that-express-msln-and/ 2026-04-07T03:58:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-granted-breakthrough-therapy-designation-btd-to-plixorafenib-for-the-treatment-of-adult-patients-with-braf-v600e-mutated-high-grade-glioma-hgg/ 2026-04-07T03:59:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-clears-the-ind-to-proceed-to-ph-1b-clinical-trial-with-aky-251/ 2026-04-07T04:15:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-review-extension-of-bla-for-orca-t-for-the-treatment-of-heme-malignancies/ 2026-04-07T04:18:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/nda-submitted-to-the-fda-for-bezuclastinib-in-imatinib-treated-gist-patients/ 2026-04-07T04:20:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ind-submitted-to-fda-for-telomir-1-telomir-zn-in-advanced-and-metastatic-tnbc/ 2026-04-07T04:22:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-accepts-priority-review-of-nda-for-lirafugratinib-as-2l-cholangiocarcinoma-treatment/ 2026-04-07T04:24:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/type-c-fda-meeting-announced-to-discuss-single-arm-registrational-pathway-for-pelareorep-in-anal-cancer/ 2026-04-07T04:25:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/os-beyond-two-years-for-eight-patients-treated-with-ateganosine-sequenced-with-cemiplimab-in-parts-a-and-b-of-ph-2-thio-101-trial-in-nsclc-reported/ 2026-04-07T04:28:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ivonescimab-shows-qol-benefits-in-chemo-free-1l-nsclc/ 2026-04-07T04:29:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-in-for-ph-1-combination-study-of-ide849-and-ide161-in-dll3-upregulated-solid-tumor-indications-including-sclc-nets-necs-and-melanoma/ 2026-04-07T04:31:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-in-for-ph-1-trial-of-ide574-in-solid-tumor-indications-including-breast-prostate-crc-and-lung-cancer/ 2026-04-07T04:35:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/transgene-and-nec-bio-sign-license-agreement-to-prepare-the-next-steps-of-the-development-of-tg4050-in-head-and-neck-cancer/ 2026-04-07T04:36:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/onkure-therapeutics-announces-oversubscribed-150m-private-placement-to-advance-two-pi3k%ce%b1-pan-mutant-selective-inhibitors-in-breast-cancer-and-vascular-anomalies/ 2026-04-07T04:37:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/stipple-bio-launches-with-100m-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline/ 2026-04-07T04:39:30+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/aprea-therapeutics-announces-closing-of-oversubscribed-30m-private-placement/ 2026-04-07T04:40:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/akari-therapeutics-announces-strategic-partnership-with-wuxi-xdc-to-advance-development-of-novel-adc-payload-targeting-rna-splicing/ 2026-04-07T04:42:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer/ 2026-04-07T04:43:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/imfinzi-imjudo-combined-with-lenvatinib-and-tace-demonstrated-a-statistically-significant-pfs-improvement-in-embolisation-eligible-unresectable-liver-cancer-in-emerald-3-ph-3-trial/ 2026-04-07T04:47:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/rinzimetostat-rp3d-in-combination-with-darolutamide-selected-for-himalayas-1-ph-3-global-study-with-dose-optimization-data/ 2026-04-07T04:49:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/frontier-medicines-announces-exclusive-licensing-agreement-for-fmc-220-with-lg-chem/ 2026-04-07T04:51:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-clears-the-ind-for-can016-for-adc-pre-treated-solid-tumors/ 2026-04-07T04:52:14+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/neoadjuvant-anbenitamab-meets-primary-endpoint-in-ph-3-her2-positive-breast-cancer-trial/ 2026-04-07T04:53:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-3-rasolute-303-trial-of-daraxonrasib-in-1l-metastatic-pancreatic-cancer/ 2026-04-07T04:54:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-with-amgen-to-evaluate-zocilurtatug-pelitecan-in-combination-with-imdelltra/ 2026-04-07T04:56:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-granted-rmat-designation-to-cb-011-in-rrmm-patients/ 2026-04-07T04:58:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/complete-response-letter-from-the-fda-for-rp1-biologics-license-application-for-the-treatment-of-advanced-melanoma/ 2026-04-15T10:24:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-approves-ind-application-for-tqb3205-in-advanced-malignant-tumors/ 2026-04-15T10:26:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ct-p71-received-fast-track-designation-from-us-fda-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma/ 2026-04-15T10:27:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-orphan-drug-designation-granted-to-reyobiq-in-pediatric-malignant-gliomas/ 2026-04-15T10:28:18+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-orphan-drug-designation-for-biliary-tract-cancer-treatment-tovecimig-abl001/ 2026-04-15T10:29:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/alignment-with-fda-on-registration-path-for-crb-701-in-2l-hnscc-and-cervical-cancer-announced/ 2026-04-15T10:31:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/results-from-ph-2-imgn853-0420-trial-show-orr-of-62-7-with-elahere-chemo-followed-by-elahere-monotherapy-in-patients-with-%e2%89%a550-fr%ce%b1-expressing-psoc/ 2026-04-15T10:32:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/2-year-median-follow-up-data-on-avmapki-fakzynja-combination-therapy-in-recurrent-low-grade-serous-ovarian-cancer-presented/ 2026-04-15T10:32:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/updated-data-on-cadonilimab-combination-therapy-in-pd-l1-inhibitor-resistant-advanced-nsclc-presented/ 2026-04-15T10:33:41+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/comprehensive-response-to-fda-opdp-submitted-regarding-issues-related-to-a-television-advertisement-and-a-podcast-for-anktiva/ 2026-04-15T10:35:59+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/updated-data-from-ph-1b-2-study-of-muzastotug-keytruda-in-late-line-patients-with-mss-crc-demonstrate-improved-durability-of-response/ 2026-04-15T10:36:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-topline-results-from-ph-2-3-registrational-trial-optimum-02-of-darovasertib-crizotinib-combo-in-1l-hla-a0201-neg-metastatic-uveal-melanoma-announced/ 2026-04-15T10:37:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/fda-removes-partial-clinical-hold-on-linnet-study/ 2026-04-15T10:38:47+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/recruitment-in-amplicity-trial-halted-after-three-dose-limiting-toxicities-dlts-related-to-mfolfirinox/ 2026-04-15T10:39:51+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/oricell-therapeutics-closes-110-million-pre-ipo-financing-for-global-development-of-solid-tumor-car-t-therapies/ 2026-04-15T10:40:24+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/clinical-trial-collaboration-and-supply-agreement-between-boehringer-and-biontech-to-conduct-a-ph-1b-2-trial-of-obrixtamig-with-pumitamig-in-es-sclc/ 2026-04-15T10:41:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/gilead-to-acquire-tubulis-adding-adc-and-next-gen-platform-to-further-strengthen-oncology-pipeline/ 2026-04-15T10:42:23+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/boston-oncology-cgt-holding-to-license-xuanzhu-biopharmaceuticals-bireociclib-and-dirozalkib/ 2026-04-15T10:43:10+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/sidewinder-therapeutics-announces-137-million-series-b-financing-to-advance-precision-bispecific-adcs-into-clinical-development-for-cancer/ 2026-04-15T10:44:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/maia-biotechnology-expects-recent-33-million-capital-raise-to-fully-fund-ongoing-pivotal-ph-3-trial-of-novel-telomere-targeting-anticancer-therapy/ 2026-04-15T10:45:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/wugen-selected-for-us-fda-cmc-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-soficabtagene-geleucel/ 2026-04-15T10:47:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/incyclix-bio-raises-additional-5-million-in-series-b-financing-to-advance-clinical-trial-of-inx-315-in-patients-with-cdk4-6-inhibitor-resistant-er-her2-breast-cancer-or-ccne1-amplified-solid-tumors/ 2026-04-15T10:48:03+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ifinatamab-deruxtecan-granted-priority-review-in-the-us-for-adult-patients-with-previously-treated-es-sclc/ 2026-04-15T10:49:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/trastuzumab-pamirtecan-demonstrated-clinically-meaningful-efficacy-in-patients-with-her2-expressing-recurrent-endometrial-cancer/ 2026-04-15T10:49:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-1-2a-clinical-trial-of-glix1-initiated-in-gbm/ 2026-04-15T10:50:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/oxford-biotherapeutics-enters-strategic-collaboration-with-bms-to-discover-and-develop-next-gen-t-cell-engagers-for-solid-tumours/ 2026-04-15T10:51:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/nda-submitted-to-fda-for-neladalkib-in-tki-pre-treated-advanced-alkve-nsclc/ 2026-04-15T10:52:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/mocertatug-rezetecan-achieved-confirmed-orr-of-62-in-platinum-resistant-ovarian-cancer-proc-and-67-in-recurrent-advanced-endometrial-cancer-in-behold-1-study/ 2026-04-15T10:52:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/adagene-and-incyte-to-evaluate-muzastotug-adg126-in-combination-with-inca33890-in-patients-with-mss-crc/ 2026-04-15T10:53:43+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer/ 2026-04-15T10:54:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/c4-therapeutics-and-roche-enter-new-collaboration-agreement-focused-on-discovering-and-developing-degrader-antibody-conjugates-dacs/ 2026-04-15T11:02:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/blenrep-belantamab-mafodotin-approved-in-china-for-treatment-of-2l-relapsed-refractory-multiple-myeloma/ 2026-04-21T14:00:32+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/zepzelca-tecentriq-approved-for-use-in-australia-and-singapore-as-1l-maintenance-treatment-for-adult-patients-with-es-sclc/ 2026-04-21T14:03:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fast-track-designation-granted-to-opn-6602-for-the-treatment-of-multiple-myeloma/ 2026-04-21T14:06:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/odm-212-granted-orphan-drug-designation-in-mesothelioma-by-the-us-fda/ 2026-04-21T14:11:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-orphan-drug-designation-for-eftilagimod-alfa-in-soft-tissue-sarcoma/ 2026-04-21T14:15:46+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/us-fda-grants-priority-review-to-sbla-for-padcev-keytruda-as-perioperative-treatment-for-mibc-regardless-of-cisplatin-eligibility/ 2026-04-21T14:18:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/orphan-drug-designation-application-submitted-to-us-fda-for-skinject-for-treating-basal-cell-carcinoma-bcc-in-patients-with-gorlin-syndrome/ 2026-04-21T14:20:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ifinatamab-deruxtecan-granted-priority-review-in-the-us-for-adult-patients-with-previously-treated-es-sclc-who-experienced-disease-progression-on-or-after-platinum-based-chemotherapy/ 2026-04-21T14:22:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/jaypirca-pirtobrutinib-significantly-extended-pfs-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cll-sll/ 2026-04-21T14:23:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-2-trial-of-botensilimab-bot-balstilimab-bal-agent-797-in-gej-cancer-shows-77-dcr-and-long-term-survival-beyond-20-months-in-heavily-pretreated-patients/ 2026-04-21T14:25:02+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/kimmtrak-doubles-the-5-yr-survival-rate-for-1l-hla-a0201-patients-with-metastatic-uveal-melanoma/ 2026-04-21T14:27:00+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/promising-clinical-activity-and-favorable-safety-profile-reported-for-ace-106-in-solid-tumors/ 2026-04-21T14:28:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/results-announced-from-ph-2-skb264-ii-06-mk-2870-002-study-of-sacituzumab-tirumotecan-sac-tmt-in-ovarian-cancer-cohort-and-the-cervical-cancer-cohorts/ 2026-04-21T14:31:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/ph-2-data-for-mirvetuximab-soravtansine-gynx-elahere-in-platinum-sensitive-ovarian-cancer-psoc-presented/ 2026-04-21T14:33:08+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/safety-and-tolerability-of-rinatabart-sesutecan-rina-s-in-combination-with-bevacizumab-in-advanced-ovarian-cancer-presented/ 2026-04-21T14:35:50+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/positive-pds01adc-interim-ph-2-trial-data-from-stage-1-of-nci-led-metastatic-crc-trial-published/ 2026-04-21T14:38:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/nature-medicine-publishes-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-chemo-in-1l-metastatic-pancreatic-ductal-adenocarcinoma/ 2026-04-21T14:39:44+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/third-patient-dosed-in-cohort-2-of-ph-1-cer-1236-trial/ 2026-04-21T14:41:06+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/crossbridge-bio-enters-an-agreement-to-be-acquired-by-eli-lilly-to-advance-next-gen-dual-payload-adcs/ 2026-04-21T14:42:29+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform/ 2026-04-21T14:44:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-ph-2-sarcoma-trial-of-stc-15/ 2026-04-21T14:45:21+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/telix-and-regeneron-announce-strategic-radiopharma-collaboration/ 2026-04-21T14:46:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/obsidian-therapeutics-and-galera-therapeutics-announce-merger-agreement-and-350-million-concurrent-private-placement/ 2026-04-21T14:54:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/senhwa-biosciences-secures-strategic-backing-from-global-investor-gem-with-up-to-nt500-million-to-accelerate-ai-driven-drug-development/ 2026-04-21T14:55:17+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/iaso-bio-establishes-international-partnership-with-instituto-butantan-to-develop-innovative-therapy-for-hematological-cancer/ 2026-04-21T14:58:12+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/supplemental-bla-submitted-to-fda-for-bizengri-zenocutuzumab-zbco-in-nrg1-fusion-positive-cholangiocarcinoma-included-in-updated-nccn-guidelines/ 2026-04-21T14:59:16+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/daraxonrasib-demonstrates-unprecedented-os-benefit-in-ph-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic-cancer/ 2026-04-21T15:00:31+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-us-site-activated-for-ongoing-international-ph-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting-advanced-nsclc/ 2026-04-21T15:01:49+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies/ 2026-04-21T15:03:35+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-fast-track-designation-for-lunresertib-in-combination-with-zedoresertib-for-genomic-defined-platinum-resistant-ovarian-cancer/ 2026-04-21T15:05:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/darlifarnib-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-rcc-previously-treated-with-cabozantinib/ 2026-04-21T15:07:37+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/boehringer-ingelheim-and-zai-lab-announce-collaboration-on-dll3-targeting-t-cell-engager-and-adc-combination-in-sclc-and-other-neuroendocrine-carcinomas/ 2026-04-21T15:09:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/ph-3-trial-of-lae002-afuresertib-for-breast-cancer-met-pfs-primary-endpoint/ 2026-04-21T15:10:36+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/terremoto-biosciences-closes-108-million-series-c-financing-to-advance-selective-akt1-inhibitors-in-oncology/ 2026-04-21T15:12:25+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/fda-fast-track-designation-for-ng-350a-for-the-treatment-of-mmr-proficient-locally-advanced-rectal-cancer/ 2026-04-27T20:32:03+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ojemda-approved-in-the-eu-in-r-r-pediatric-low-grade-glioma-regardless-of-braf-alteration/ 2026-04-28T11:01:28+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_drug-approvals.png https://onco-this-week.com/fda-approves-clinical-trial-application-for-syh2059/ 2026-04-28T11:09:41+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/clinical-trial-application-approved-for-cryptivax-1001-ovact-trial-in-advanced-high-grade-serous-ovarian-cancer/ 2026-04-28T11:10:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-extends-review-period-for-sarclisa-isatuximab-irfc-sc-bla-by-up-to-3-months-new-target-action-date-july-23-2026/ 2026-04-28T11:10:54+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/fda-fast-track-designation-for-bbo-11818-for-advanced-kras-mutant-pancreatic-ductal-adenocarcinoma/ 2026-04-28T11:12:13+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/ema-application-for-adding-new-indication-for-pluvicto-withdrawn/ 2026-04-28T11:13:03+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/type-c-meeting-with-fda-provides-alignment-on-design-of-a-pivotal-clinical-study-to-support-approval-of-pelareorep-in-patients-with-unresectable-metastatic-scac/ 2026-04-28T11:14:57+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/early-results-announced-from-trial-of-nadunolimab-in-mds-and-aml/ 2026-04-28T11:15:56+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/updated-interim-data-from-ph-1-2-study-of-ozekibart-inbrx-109-folfiri-in-patients-with-metastatic-crc-announced/ 2026-04-28T11:16:44+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/failed-trial-phase-3-litespark-012-trial-of-keytruda-lenvima-and-welireg-did-not-meet-the-dual-primary-endpoints-of-pfs-and-os-in-1l-rcc/ 2026-04-28T11:27:09+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/nature-publishes-positive-pancreatic-cancer-ph-1b-data-for-np137/ 2026-04-28T11:28:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/lp-300-demonstrates-8-3-month-median-pfs-in-patients-with-egfr-l858r-lung-cancer-after-targeted-therapy-failure-with-no-added-toxicity/ 2026-04-28T11:29:07+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/japanese-ph-2-registration-directed-trial-of-ziftomenib-initiated-in-r-r-npm1-m-aml/ 2026-04-28T11:30:42+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/ph-3-star-121-study-of-domvanalimab-zimberelimab-and-chemo-vs-pembrolizumab-chemo-in-1l-nsclc-to-be-discontinued/ 2026-04-28T11:31:15+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-participant-dosed-in-ph-1-2-trial-of-rptr-1-201-in-advanced-solid-tumors/ 2026-04-28T11:31:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-pancreatic-cancer-patient-in-europe-treated-with-alpha-dart-in-french-multicenter-acapella-clinical-trial/ 2026-04-28T11:32:40+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/adce-t02-enters-cohort-expansion-portion-of-the-tiffany-01-study-in-advanced-solid-tumors/ 2026-04-28T11:33:19+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/dose-expansion-in-clinical-study-of-spevatamig-chemo-for-treatment-of-biliary-tract-cancer/ 2026-04-28T11:34:20+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/first-patient-dosed-in-expanded-access-program-for-leronlimab-in-tnbc/ 2026-04-28T11:34:53+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/lilly-to-acquire-ajax-therapeutics-to-advance-outcomes-for-patients-with-myelofibrosis-and-polycythemia-vera/ 2026-04-28T11:36:27+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_business-news.png https://onco-this-week.com/conference-coverage-aacr-2026/ 2026-04-28T11:39:48+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_conference-coverage.png https://onco-this-week.com/fda-accepts-for-priority-review-supplemental-bla-for-ziihera-zanidatamab-hrii-combo-in-1l-her2-locally-advanced-or-metastatic-gea/ 2026-04-28T12:04:52+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-in-1l-metastatic-breast-cancer-announced/ 2026-04-28T12:05:34+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/first-patient-dosed-in-ph-1-2-study-of-mt-304-in-her2-positive-solid-tumors/ 2026-04-28T12:06:26+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png https://onco-this-week.com/taletrectinib-ibtrozi-added-as-recommended-option-to-nccn-guidelines-for-cns-cancers/ 2026-04-28T12:07:11+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_regulatory-news.png https://onco-this-week.com/tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-ph-2-3-study-in-patients-with-biliary-tract-cancer/ 2026-04-28T12:08:04+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-results.png https://onco-this-week.com/teadco-ph-1b-2-basket-trial-of-odm-212-soc-initiated-in-patients-with-select-advanced-solid-tumors/ 2026-04-28T12:08:45+00:00 https://onco-this-week.com/wp-content/uploads/2024/02/Onco-this-week_FI_trial-status.png